4BIO Capital
Investment Details
Investor Type
Venture Capital
Asset Class Focus
Venture Capital
Stage Focus
Seed, Early Stage, Series A, Series B, Growth, Late Stage, Pre-IPO
Geographical Focus
United States, United Kingdom, Germany, Japan, China, Switzerland
Industries Focus
- Healthcare
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Regenerative Medicine
- Immunotherapy
- Oncology
- Neurology
- Cardiology
- Endocrinology
- Infectious Diseases
- Genomics
- Rare Diseases
- Orphan Drugs
Investment Size:
5,000,000 to 50,000,000 USD
Investor Details Founded: 2014
4BIO Capital is a London-based venture capital firm focused solely on the advanced and emerging therapies sector. The firm aims to invest in, support, and grow early-stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to potentially curative therapies for all patients. Specifically, 4BIO seeks viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome.
The 4BIO team comprises leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in prestigious academic journals, including Nature, The Lancet, Cell, and the New England Journal of Medicine. This expertise provides 4BIO with an unrivaled network within the advanced therapy sector and a unique understanding of the criteria that define a successful investment opportunity in this space.
4BIO Capital has a global footprint across the United States, Europe, and Asia, with an objective to create, invest in, support, and grow early-stage companies. The firm is currently investing out of its Fund III, having secured support from prominent global institutional investors, including the Children’s Minnesota, UPMC, Development Bank of Japan, Kyowa Kirin, Exor, and many other endowments and foundations.
Requirements
- Focus on advanced and emerging therapies
- Address high unmet medical needs
- Early-stage companies
- Viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome
Contact
[Official Website Hidden]
[HQ Location Hidden]
[Email Hidden]
[Contact Number Hidden]
Portfolio Companies
- Araris Biotech
- March Biosciences
- Trogenix
Mentioned In
-
$24.95
-
$49.95
-
$19.95
-
$19.95
-
$24.95
-
$99.00
Claim this Investor
Are you an official representative of 4BIO Capital?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim